CARMAT (FR0010907956, ALCAR), the developer of the world’s most advanced total artificial heart, has achieved a significant milestone with the successful implantation of 100 Aeson® artificial hearts. This marks a key moment in the company’s ongoing efforts to provide a therapeutic alternative for those suffering from advanced biventricular heart failure.
Successful Dual Implantations Mark Key Achievement
The 99th and 100th Aeson® implants were carried out on February 7, 2025, at the Lille and Dijon university hospitals in France. The procedures were performed simultaneously by the teams of Prof. Vincentelli and Prof. Bouchot, as part of the EFICAS clinical study.
Rapid Growth in Implant Numbers
The first 50 implants took place over a span of 10 years, starting in 2013 with the first human implantation of Aeson® and continuing through the end of 2023. However, since the beginning of 2024, the rate of implants has accelerated dramatically, with 50 implants completed in just over a year.
This acceleration signals the expanding adoption of the Aeson® artificial heart across Europe, as healthcare professionals increasingly integrate the device into their treatment protocols. The growing confidence in Aeson® is also a testament to its success in meeting a critical medical need.
Strong Momentum for Future Growth
This momentum aligns with CARMAT’s goal to double its sales in 2025 and solidify Aeson® as a leading therapy for advanced heart failure. The company’s commitment to innovation and patient care continues to drive its progress in the field.
CEO’s Statement on the Milestone
Stéphane Piat, CEO of CARMAT, commented on the achievement: “A year ago, we celebrated the milestone of 50 implants. Now, with the 100th implant, Aeson® proves it addresses a genuine therapeutic need. I thank the healthcare professionals, CARMAT teams, and the patients and families who are part of this groundbreaking journey. Together, we are shaping the future of advanced heart failure treatment with our innovative artificial heart.”
Related topics:
